Cui Xiangmin 4/A

What Happened

• Director Cui Xiangmin was granted 76,923 options to purchase Class A common stock of Nuvation Bio (NUVB) in a grant reported for the 2026-02-27 award date. The Form 4 records the acquisition as a derivative option award with an acquisition amount shown as $0.00 (i.e., an option grant, not an exercised purchase or sale). This was an award/compensation event rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-02-27 (award date). Report originally filed on 2026-03-03 and this Form 4 was amended on 2026-05-26 to correct the reported amount.
• Award size: 76,923 options (amended — original filing incorrectly reported 74,813; corrected upward by 2,110 options).
• Price/value shown on Form 4: $0.00 acquisition amount (derivative award); no cash paid or shares sold in this filing.
• Shares owned after transaction: not disclosed on this filing.
• Vesting: options vest 1/24 of the total on the one‑month anniversary of 1/1/2026 and monthly thereafter over the next 23 months, subject to continued service (per footnote).
• Filing status: AMENDED filing to correct an administrative error in the prior Form 4 (the original Form 4 was filed 2026-03-03; this amendment was filed 2026-05-26).

Context

• This is a grant of options (a derivative award) — the options do not represent immediately tradeable shares until they vest and the holder exercises them (exercise price and exercise events are not part of this Form 4 disclosure).
• The amendment corrects the public record; the original timely Form 4 misstated the number of options awarded. This type of award is typically part of director compensation and should not be interpreted by itself as a buy/sell signal.